Marco Lodrini

1.8k total citations
24 papers, 1.1k citations indexed

About

Marco Lodrini is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Marco Lodrini has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Neurology and 8 papers in Oncology. Recurrent topics in Marco Lodrini's work include Neuroblastoma Research and Treatments (13 papers), Histone Deacetylase Inhibitors Research (11 papers) and Protein Degradation and Inhibitors (9 papers). Marco Lodrini is often cited by papers focused on Neuroblastoma Research and Treatments (13 papers), Histone Deacetylase Inhibitors Research (11 papers) and Protein Degradation and Inhibitors (9 papers). Marco Lodrini collaborates with scholars based in Germany, United States and France. Marco Lodrini's co-authors include Hedwig E. Deubzer, Ina Oehme, Olaf Witt, Till Milde, Stefan M. Pfister, Andrey Korshunov, Annette Kopp‐Schneider, Andreas von Deimling, Marcel Kool and Andreas E. Kulozik and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Molecular Biology.

In The Last Decade

Marco Lodrini

22 papers receiving 1.1k citations

Peers

Countries citing papers authored by Marco Lodrini

Since Specialization

Citations

This map shows the geographic impact of Marco Lodrini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Lodrini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Lodrini more than expected).

Fields of papers citing papers by Marco Lodrini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Lodrini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Lodrini. The network helps show where Marco Lodrini may publish in the future.

Co-authorship network of co-authors of Marco Lodrini

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Lodrini. A scholar is included among the top collaborators of Marco Lodrini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Lodrini. Marco Lodrini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma 2025 ·Cancer Research Communications ·(unknown), Annabell Szymansky, (unknown), Kathy Astrahantseff, Carolina Rosswog, Anne Thorwarth, (unknown), Rocío Chamorro González, Patrick Hundsdörfer, Kathrin Hauptmann, Karin Schmelz, Dennis Gürgen, Julian M.M. Rogasch, Anton G. Henssen, Matthias Fischer, Johannes H. Schulte, Cornelia Eckert, Angelika Eggert, Marco Lodrini, Hedwig E. Deubzer	0
2	Management of Busulfan-Induced Lung Injury in Pediatric Patients with High-Risk Neuroblastoma 2024 ·Journal of Clinical Medicine ·(unknown), Anne Thorwarth, (unknown), (unknown), Kathy Astrahantseff, Annabell Szymansky, Marco Lodrini, Simon Veldhoen, Alexander Gratopp, Marcus Mall, Angelika Eggert, Hedwig E. Deubzer	1
3	Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis 2024 ·Journal of Clinical Medicine ·Annika Sprüssel, Takayoshi Suzuki, Naoki Miyata, Kathy Astrahantseff, Annabell Szymansky, Joern Toedling, (unknown), (unknown), Marco Lodrini, Annette Künkele, Matthias Truß, Lukas C. Heukamp, Susanne Mathia, Falk Hertwig, Christian Rosenberger, Angelika Eggert, Hedwig E. Deubzer, Johannes H. Schulte	0
4	Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction 2020 ·Journal of Molecular Diagnostics ·(unknown), Annika Sprüssel, (unknown), Kathy Astrahantseff, (unknown), Karin Schmelz, Joern Toedling, Johannes H. Schulte, Matthias Fischer, (unknown), Dieter Beule, Ulrich Keilholz, Angelika Eggert, Hedwig E. Deubzer, Marco Lodrini	11
5	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy againstMYCN‐amplified neuroblastoma 2020 ·International Journal of Cancer ·(unknown), Christin Zasada, Katharina Baum, (unknown), Guido Mastrobuoni, Marco Lodrini, Kathy Astrahantseff, Annika Winkler, Johannes H. Schulte, (unknown), Martin Forbes, Patrick Hundsdoerfer, (unknown), Jens Hoffmann, Jana Wolf, Angelika Eggert, Stefan Kempa, Hedwig E. Deubzer	15
6	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival 2017 ·Cell Death and Disease ·Theresa Thole, Marco Lodrini, (unknown), (unknown), (unknown), Thomas Hielscher, Annette Kopp‐Schneider, Ulrike Heinicke, Simone Fulda, Olaf Witt, Angelika Eggert, Matthias Fischer, Hedwig E. Deubzer	48
7	Using droplet digital PCR to analyzeMYCNandALKcopy number in plasma from patients with neuroblastoma 2017 ·Oncotarget ·Marco Lodrini, Annika Sprüssel, Kathy Astrahantseff, (unknown), Robert Konschak, Holger N. Lode, Matthias Fischer, Ulrich Keilholz, Angelika Eggert, Hedwig E. Deubzer	50
8	Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells 2016 ·Journal of Proteome Research ·Marco Lodrini, Gereon Poschmann, (unknown), (unknown), Daniel Dreidax, Olaf Witt, Thomas Höfer, Helmut E. Meyer, Kai Stühler, Angelika Eggert, Hedwig E. Deubzer	6
9	Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas 2013 ·Autophagy ·Ina Oehme, Marco Lodrini, Nathan Brady, Olaf Witt	17
10	GRHL1 inhibits tumorigenicity and is a prognostic marker in neuroblastoma 2013 ·Klinische Pädiatrie ·(unknown), Marco Lodrini, (unknown), Theresa Thole, Annette Kopp‐Schneider, David Capper, Andreas von Deimling, Ina Oehme, (unknown), Till Milde, Frank Roels, Michael B. Fischer, (unknown), Olaf Witt, (unknown)	1
11	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma 2013 ·Nucleic Acids Research ·Marco Lodrini, Ina Oehme, Christina I. Schroeder, Till Milde, (unknown), Annette Kopp‐Schneider, Johannes H. Schulte, Matthias Fischer, Katleen De Preter, Filip Pattyn, M. Castoldi, Martina U. Muckenthaler, Andreas E. Kulozik, Frank Westermann, Olaf Witt, Hedwig E. Deubzer	75
12	HDAC11 is a novel drug target in carcinomas 2012 ·International Journal of Cancer ·Hedwig E. Deubzer, (unknown), Ina Oehme, Marco Lodrini, Bernard Haendler, Anette Sommer, Olaf Witt	90
13	Nestin Expression Identifies Ependymoma Patients with Poor Outcome 2012 ·Brain Pathology ·Till Milde, Thomas Hielscher, Hendrik Witt, Marcel Kool, Stephen C. Mack, Hedwig E. Deubzer, Ina Oehme, Marco Lodrini, Axel Benner, Michael D. Taylor, Andreas von Deimling, Andreas E. Kulozik, Stefan M. Pfister, Olaf Witt, Andrey Korshunov	36
14	HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment 2012 ·Journal of Neuro-Oncology ·Till Milde, Marco Lodrini, Larissa Savelyeva, Andrey Korshunov, Marcel Kool, (unknown), André Saraiva Leão Marcelo Antunes, Ina Oehme, Arnulf Pekrun, Stefan M. Pfister, Andreas E. Kulozik, Olaf Witt, Hedwig E. Deubzer	84
15	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat 2011 ·Acta Neuropathologica ·Till Milde, Susanne Kleber, Andrey Korshunov, Hendrik Witt, Thomas Hielscher, Philipp Koch, Hans‐Georg Kopp, Manfred Jugold, Hedwig E. Deubzer, Ina Oehme, Marco Lodrini, Hermann-Josef Gröne, Axel Benner, Oliver Brüstle, Richard J. Gilbertson, Andreas von Deimling, Andreas E. Kulozik, Stefan M. Pfister, Ana Martín-Villalba, Olaf Witt	58
16	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth 2010 ·Clinical Cancer Research ·Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp‐Schneider, Marc Remke, Paul A. Northcott, Hedwig E. Deubzer, Marco Lodrini, Michael D. Taylor, Andreas von Deimling, Stefan M. Pfister, Olaf Witt	158
17	Targeting Histone Deacetylases in Neuroblastoma 2009 ·Current Pharmaceutical Design ·Olaf Witt, Hedwig E. Deubzer, Marco Lodrini, Till Milde, Ina Oehme	53
18	p160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain 2008 ·Nucleic Acids Research ·Marco Lodrini, (unknown), Nicolas Coudevylle, Christian Griesinger, Stefan Becker, Edith Pfitzner	17
19	Coactivators in Gene Regulation by STAT5 2005 ·Vitamins and hormones ·Claudia Litterst, (unknown), Marco Lodrini, Edith Pfitzner	13
20	Structure of the NCoA-1/SRC-1 PAS-B Domain Bound to the LXXLL Motif of the STAT6 Transactivation Domain 2004 ·Journal of Molecular Biology ·Adelia Razeto, V. Ramakrishnan, Claudia Litterst, Karin Giller, Christian Griesinger, Teresa Carlomagno, Nils‐Alexander Lakomek, Thomas Heimburg, Marco Lodrini, Edith Pfitzner, Stefan Becker	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact